These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3691871)

  • 41. [Action of Persantin and nitroglycerin on systemic and coronary hemodynamics in the dog. Preliminary note].
    Pandolfo G; Uslenghi E; Dessy P; Gagna C; Brocchi G; Giannini R; Campus S
    Minerva Cardioangiol; 1970 Oct; 18(10):589-93. PubMed ID: 4993306
    [No Abstract]   [Full Text] [Related]  

  • 42. Interleukin-21 as a new therapeutic target for immune-mediated diseases.
    Monteleone G; Pallone F; Macdonald TT
    Trends Pharmacol Sci; 2009 Aug; 30(8):441-7. PubMed ID: 19616319
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Action potentials of cardiomyocytes and spike activity of the neural components of the vagosympathetic reflex after immune damage to the heart].
    Shaban VM; Bidzilia IuP; Pavliuchenko VB
    Fiziol Zh (1978); 1987; 33(1):63-8. PubMed ID: 3556644
    [No Abstract]   [Full Text] [Related]  

  • 44. [Mechanism of the development of lymphogenic cardiomyopathy as revealed by electron microscopy].
    Jellinek H; Füzesi S; Hársing J; Solti F; Gloviczky P; Szlávy L
    Morphol Igazsagugyi Orv Sz; 1981 Oct; 21(4):266-72. PubMed ID: 7322180
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Immune disorders in tonsillogenic lesions of the heart].
    Dutka RIa
    Vrach Delo; 1988 Nov; (11):55-7. PubMed ID: 3238978
    [No Abstract]   [Full Text] [Related]  

  • 46. Characteristics of chronic left ventricular dysfunction induced by coronary embolization in a canine model.
    Blaustein AS; Hoit BD; Wexler LF; Ashraf M; Ramrakhyani K; Matoba R; Gabel M; Millard RW
    Am J Cardiovasc Pathol; 1995; 5(1):32-48. PubMed ID: 8838155
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Adrenoreactivity of the contractile myocardium and coronary arteries in chronic overloading and acute ischemic damage to the heart].
    Bobkov IuI; Pimenova TI; Frolova TM; Shevliakova NI
    Patol Fiziol Eksp Ter; 1983; (2):8-11. PubMed ID: 6856362
    [No Abstract]   [Full Text] [Related]  

  • 48. [The cardioprotective action of 18-dehydroglycyrrhetic acid in experimental myocardial damage].
    Zakirov NU; Aĭzimov MI; Kurmukov AG
    Eksp Klin Farmakol; 1999; 62(2):19-21. PubMed ID: 10340122
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Reperfusion damages to the heart in acute transitory coronary failure and their prevention with myophedrin].
    Vasilevskaia TA; Litvitskiĭ PF
    Biull Eksp Biol Med; 1985 Jul; 100(7):97-100. PubMed ID: 4016248
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The limitation of lipid hyperperoxidation and the prevention of stressor damages to the heart by glycine derivatives].
    Malyshev VV; Oshchepkova OM; Seminskiĭ IZh; Nefedova TV; Morozova TP
    Eksp Klin Farmakol; 1996; 59(5):23-5. PubMed ID: 9026203
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Effect of etimizol and propylnorantifein on myocardial respiratory enzymatic activity in a neurogenic lesion].
    Bul'on VV
    Biull Eksp Biol Med; 1980 Aug; 90(8):180-2. PubMed ID: 7407391
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Prophylactic use of Neoton in cardiac failure in patients with myocardial infarction].
    Perepech NB; Nedoshivin AO; Kutuzova A'E
    Klin Med (Mosk); 1997; 75(10):52-4. PubMed ID: 9490342
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Prophylactic immunocorrection with sodium nucleinate].
    Zemskov AM; Zemskov VM; Kuralesin NA; Mikhaĭlov AA; Snopkova VA; Abdulina GA; Evstratov IuA
    Med Tr Prom Ekol; 1995; (4):34-6. PubMed ID: 7613784
    [No Abstract]   [Full Text] [Related]  

  • 54. [Protective effect of Neoton during cardiovascular surgery. Hemodynamic and biochemical aspects].
    Záhorec R; Holomán H; Bilcíková E; Simo M; Tomlain R; Pechán I
    Vnitr Lek; 1993 Feb; 39(2):143-52. PubMed ID: 8506661
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Modeling dystrophic myocardial lesions in dogs].
    Sagach VF
    Fiziol Zh; 1975; 21(2):201-6. PubMed ID: 1126477
    [No Abstract]   [Full Text] [Related]  

  • 56. [Indications for the use of phosphocreatine in cardiology].
    Pinelli G; Di Pasquale G; Alberici S; Manini G; Coluccini M
    Clin Ter; 1982 Feb; 100(3):261-79. PubMed ID: 7060343
    [No Abstract]   [Full Text] [Related]  

  • 57. Pathophysiology of cardiomyopathies: Part II. Drug-induced and other interventions.
    Gwathmey JK; Davidoff AJ
    Curr Opin Cardiol; 1994 May; 9(3):369-78. PubMed ID: 8049595
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The anti-arrhythmic action of exogenous creatine phosphate and its effect on myocardial electrophysiological parameters in acute heart failure].
    Khanina NIa; Savel'ev VA; Vikulova OV
    Eksp Klin Farmakol; 1993; 56(2):26-8. PubMed ID: 8348031
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Changes in the structural components of the wall of small vessels and the peripheral blood composition in immune and hypoxic actions on the heart].
    Sirotina MF
    Fiziol Zh (1978); 1982; 28(5):578-82. PubMed ID: 7141028
    [No Abstract]   [Full Text] [Related]  

  • 60. [Mechanism of the action of plasmin in myocardial damage due to coagulation].
    Monastyrskiĭ VA; Voroniak MI; Birka II; Gaĭda AV; Magerovskiĭ IuV
    Vrach Delo; 1988 Mar; (3):70-3. PubMed ID: 2969161
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.